|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
(1) The plasma PAI-1 levels of group A (60.39 ± 17.01 ng/L), group B (68.76 ± 17.81 ng/L) and group C and (68.63 ± 18.30 ng/L) are higher than that of controls (46.26 ± 26.04 ng/L); (2) Patients with genotype 4G/4G tended to exhibit higher PAI-1 level; (3) The distribution frequency of genotype 4G/4G in group C was significantly higher than in group A (42.4% vs. 28.7%, p < 0.05) and (4) In type 2 diabetic patients, the occurrence of diabetes nephropathy in genotype 4G/4G, 4G/5G and 5G/5G is 35.0%, 30.2% and 21.4%, respectively.
|
26616527 |
2016 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus.
|
21070757 |
2011 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
PAI-1 activity was increased in hyperlipidemic compared to healthy dogs, but there was no significant difference between dogs with hyperadrenocorticism and diabetes mellitus.
|
28266313 |
2017 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
PAI-1 deficiency did not affect the mRNA levels of iNOS and IL-6 in F4/80- and CD11b-double-positive cells from the bone marrow of the damaged femurs decreased by diabetes in mice.
|
29534207 |
2018 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
A multiple linear regression model with independent variables (age, body-mass index, total cholesterol level, triglyceride level, ACE I/D genotype, and PAI-1 genotype due to a single guanine I/D polymorphism in the PAI-1 gene) demonstrated that the triglyceride level (P = 0.0059) and ACE I/D genotype (P = 0.0372) were independent predictors of plasma PAI-1 antigen levels in a subset of the subjects without diabetes mellitus that were not taking lipid-lowering drugs.
|
10759003 |
2000 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Circulating plasminogen activator inhibitor-1 levels are elevated at an early stage of impaired glucose tolerance, resulting in diabetes and metabolic syndrome.
|
18160587 |
2008 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Compared to PBS treatment, APX3330 treatment significantly decreases plasminogen activator inhibitor type-1 (PAI-1), monocyte chemotactic protein-1 and matrix metalloproteinase 9 (MMP9) and receptor for advanced glycation endproducts expression in the ischemic brain of T1DM stroke rats.
|
29896433 |
2018 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Compared with 55 (33.3%) individuals in whom OSAS was not confirmed, OSAS patients had prolonged CLT (+12.8%), associated with higher PAI-1 antigen (+18.1%) (after adjustment for age, diabetes, and body mass index; both P < 0.01) and similar levels of TAFIa, plasmin, or antiplasmin.
|
27167858 |
2016 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Concentrations in blood of plasminogen activator inhibitor type 1 (PAI-1) and circulating free (non-esterified) fatty acids (FFA) are increased in diabetes and may accelerate atherosclerosis.
|
12669679 |
2002 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Elevated PAI-1 levels may be associated with an increased risk for diabetes as a marker for underlying endothelial dysfunction rather than by a direct effect of genetically mediated elevated levels.
|
16855181 |
2006 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Elevated plasminogen activator inhibitor-1 may contribute to vascular disease in diabetes mellitus.
|
8960834 |
1996 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated with myocardial infarction and stroke, especially in patients with diabetes.
|
15956119 |
2005 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Four proteins (Scavenger receptor cysteine rich type 1 protein M130, Fatty acid binding protein 4, Plasminogen activator inhibitor 1 and Insulin-like growth factor-binding protein 2) with a previously established association with incident diabetes and 3 proteins (Cathepsin D, Galectin-4, Paraoxonase type 3) with a novel association with incident diabetes.
|
30670722 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
From our longitudinal cohort study, we selectively recruited chronically stable HIV-infected individuals without diagnosis of diabetes mellitus at baseline (N = 62) to analyze the correlation of baseline inflammatory cytokines, including PAI-1 and whole-body insulin sensitivity, with 2-year follow-up, as measured by Matsuda Index.
|
28322572 |
2017 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
However, inflammatory biomarkers hs-CRP [hazard ratio (HR) 1.16, (95% CI 1.05 to 1.29), p=0.005], procalcitonin [HR 1.34, (95% CI 1.07 to 1.69), p=0.012] and PAI-1 [HR 1.55, (95% CI 1.37 to 1.75), p<0.001] remained significantly associated with new-onset DM, even after multivariable adjustment for established predictors of DM.
|
29074040 |
2018 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
In 45/112 patients without the established risk factors for RVO (hyper-tension, hypercholesterolemia and diabetes) or characteristics known to be associated to increased PAI-1 activity (overweight, hypertriglyceridemia, and smoking habit) the contemporary presence of ACE DD and PAI-1 4G4G genotype was significantly associated with a risk for RVO (OR = 8.26, 95% CI 1.18-57.92; p = 0.034).
|
15213845 |
2004 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
In a logistic regression analysis controlled for age, sex, BMI, and duration of diabetes, any retinopathy was significantly associated with fasting plasma glucose concentrations (P < 0.05), 2-h postload glucose (P = 0.02), and HbA1c (P = 0.008), but not with PAI-1 activity (P = 0.48).
|
9250459 |
1997 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Increased flux through HBP is required and sufficient for some of the metabolic effects of sustained, increased glucose flux, which promotes the complications of diabetes, e.g., diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase in cardiomyocytes and induction of TGF-beta and plasminogen activator inhibitor-1 in vascular smooth muscle cells, mesangial cells, and aortic endothelial cells.
|
16339923 |
2006 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Increased levels of PAI-1 and glycated low-density lipoprotein (glyLDL) were detected in patients with diabetes.
|
20630999 |
2010 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Interaction between genotype and diabetes status was estimated for nine CVD risk factors [body fat mass (FAT), body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), log-transformed fibrinogen, log-transformed triglycerides, log-transformed urinary albumin : creatinine ratio (LACR), plasminogen activator inhibitor 1 (PAI-1), systolic blood pressure (SBP), and waist-to-hip ratio (WHR)], using a maximum likelihood variance decomposition technique.
|
12673782 |
2003 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |
|
Diabetes Mellitus
|
0.300 |
Therapeutic
|
group |
RGD |
Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats.
|
10910004 |
2000 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Low-moderate arsenic exposure was positively associated with baseline fibrinogen in participants with diabetes and unexpectedly inversely associated with PAI-1.
|
28771557 |
2017 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
MTHFRA1298C and PAI-1 deletions were most frequent genetic variants in risk groups for MI in patients with diabetes mellitus (value of odds ratio sequentially [OR] = 3.79, p = 0.06 and [OR] = 5 × 10(8), p = 0.000).
|
22752805 |
2012 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Myocardial mRNA levels of interleukin-6, tumor necrosis factor-α, plasminogen activator inhibitor-1, angiotensin type 1 receptor, angiotensinogen, NADPH oxidase subunits (p47(phox), gp91(phox)), glutathione peroxidase-3. and connective tissue growth factor were increased in CRP/DM compared with Wt/DM.
|
21519150 |
2011 |